Mostrar el registro sencillo del ítem
dc.contributor.author | Willems, Luc | |
dc.contributor.author | Hasegawa, Hideki | |
dc.contributor.author | Accolla, Roberto | |
dc.contributor.author | Bangham, Charles | |
dc.contributor.author | Bazarbachi, Ali | |
dc.contributor.author | Bertazzoni, Umberto | |
dc.contributor.author | Carneiro-Proietti, Anna Barbara de Freitas | |
dc.contributor.author | Cheng, Hua | |
dc.contributor.author | Chieco-Bianchi, Luigi | |
dc.contributor.author | Ciminale, Vincenzo | |
dc.contributor.author | Coelho-dos-Reis, Jordana | |
dc.contributor.author | Esparza, José | |
dc.contributor.author | Gallo, Robert C. | |
dc.contributor.author | Gessain, Antoine | |
dc.contributor.author | Gotuzzo Herencia, José Eduardo | |
dc.contributor.author | Hall, William | |
dc.contributor.author | Harford, Joseph | |
dc.contributor.author | Hermine, Olivier | |
dc.contributor.author | Jacobson, Steven | |
dc.contributor.author | Macchi, Beatrice | |
dc.contributor.author | Macpherson, Calum | |
dc.contributor.author | Mahieux, Renaud | |
dc.contributor.author | Matsuoka, Masao | |
dc.contributor.author | Murphy, Edward | |
dc.contributor.author | Peloponese, Jean-Marie | |
dc.contributor.author | Simon, Viviana | |
dc.contributor.author | Tagaya, Yutaka | |
dc.contributor.author | Taylor, Graham P. | |
dc.contributor.author | Watanabe, Toshiki | |
dc.contributor.author | Yamano, Yoshihisa | |
dc.date.accessioned | 2019-04-25T15:46:34Z | |
dc.date.available | 2019-04-25T15:46:34Z | |
dc.date.issued | 2017 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12866/6514 | |
dc.description.abstract | Even though an estimated 10–20 million people worldwide are infected with the oncogenic retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort has been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections. In the present article, the Taskforce proposes a series of actions to expand epidemiological studies; increase research on mechanisms of HTLV-1 persistence, replication and pathogenesis; discover effective treatments; and develop prophylactic and therapeutic vaccines. | en_US |
dc.language.iso | eng | |
dc.publisher | Elsevier | |
dc.relation.ispartofseries | Antiviral Research | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.subject | Human immunodeficiency virus vaccine | en_US |
dc.subject | disease course | en_US |
dc.subject | disease transmission | en_US |
dc.subject | HTLV-1 infection | en_US |
dc.subject | human | en_US |
dc.subject | human T cell leukemia virus | en_US |
dc.subject | pathogenesis | en_US |
dc.subject | prediction | en_US |
dc.subject | priority journal | en_US |
dc.subject | research priority | en_US |
dc.subject | Review | en_US |
dc.subject | T cell leukemia | en_US |
dc.subject | tropical spastic paraparesis | en_US |
dc.subject | advisory committee | en_US |
dc.subject | cost of illness | en_US |
dc.subject | global health | en_US |
dc.subject | HTLV-1 infection | en_US |
dc.subject | Human immunodeficiency virus infection | en_US |
dc.subject | Human T-lymphotropic virus 1 | en_US |
dc.subject | isolation and purification | en_US |
dc.subject | medical research | en_US |
dc.subject | spinal cord disease | en_US |
dc.subject | transmission | en_US |
dc.subject | tropical spastic paraparesis | en_US |
dc.subject | virology | en_US |
dc.subject | Advisory Committees | en_US |
dc.subject | Biomedical Research | en_US |
dc.subject | Cost of Illness | en_US |
dc.subject | Global Health | en_US |
dc.subject | HIV Infections | en_US |
dc.subject | HTLV-I Infections | en_US |
dc.subject | Human T-lymphotropic virus 1 | en_US |
dc.subject | Humans | en_US |
dc.subject | Leukemia-Lymphoma, Adult T-Cell | en_US |
dc.subject | Paraparesis, Tropical Spastic | en_US |
dc.subject | Spinal Cord Diseases | en_US |
dc.title | Reducing the global burden of HTLV-1 infection: An agenda for research and action | en_US |
dc.type | info:eu-repo/semantics/review | |
dc.identifier.doi | https://doi.org/10.1016/j.antiviral.2016.10.015 | |
dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#1.06.02 | |
dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.01.05 | |
dc.relation.issn | 1872-9096 |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |